CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD. Financials China Resources Double-Crane Pharmaceutical Co.,Ltd.
Equities
600062
CNE000000Q94
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.77 CNY | +2.01% |
|
+2.69% | +17.04% |
| Apr. 26 | CR Double-Crane Pharmaceutical's Profit Rises 11% in Q1 as Revenue Grows 2% | MT |
| Apr. 26 | CR Double-Crane Pharmaceutical's Unit Gets Nod to Trial New Pain Medication | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 13,614 | 12,508 | 13,948 | 18,276 | 18,992 | 22,227 | - | - |
| Enterprise Value (EV) 1 | 11,835 | 10,105 | 13,948 | 18,276 | 18,992 | 22,227 | 22,227 | 22,227 |
| P/E ratio | 12.9 x | 12.4 x | 14.9 x | 15.9 x | 14.3 x | 14.9 x | 13.2 x | 12.2 x |
| Yield | 2.33% | 2.42% | - | - | 1.38% | 1.38% | 1.56% | - |
| Capitalization / Revenue | 1.45 x | 1.47 x | 1.53 x | 1.93 x | 1.86 x | 1.96 x | 1.76 x | 1.73 x |
| EV / Revenue | 1.45 x | 1.47 x | 1.53 x | 1.93 x | 1.86 x | 1.96 x | 1.76 x | 1.73 x |
| EV / EBITDA | 8.39 x | 7.8 x | 8.8 x | 9.48 x | 8.86 x | 9.58 x | 8.62 x | 8.28 x |
| EV / FCF | 11,339,571 x | 11,859,366 x | - | - | 18,451,781 x | - | - | - |
| FCF Yield | 0% | 0% | - | - | 0% | - | - | - |
| Price to Book | 1.58 x | 1.35 x | 1.41 x | 1.86 x | 1.74 x | 1.83 x | 1.64 x | 1.49 x |
| Nbr of stocks (in thousands) | 1,043,238 | 1,043,238 | 1,043,238 | 1,021,567 | 1,021,061 | 1,020,978 | - | - |
| Reference price 2 | 13.05 | 11.99 | 13.37 | 17.89 | 18.60 | 21.77 | 21.77 | 21.77 |
| Announcement Date | 3/20/20 | 3/18/21 | 3/24/22 | 3/27/23 | 3/21/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 9,381 | 8,504 | 9,112 | 9,447 | 10,222 | 11,360 | 12,645 | 12,878 |
| EBITDA 1 | 1,623 | 1,605 | 1,585 | 1,928 | 2,142 | 2,320 | 2,579 | 2,684 |
| EBIT 1 | 1,262 | 1,229 | 1,137 | 1,406 | 1,515 | 1,780 | 2,007 | 2,178 |
| Operating Margin | 13.46% | 14.46% | 12.48% | 14.88% | 14.82% | 15.67% | 15.87% | 16.92% |
| Earnings before Tax (EBT) 1 | 1,262 | 1,215 | 1,121 | 1,415 | 1,567 | 1,788 | 2,016 | 2,188 |
| Net income 1 | 1,055 | 1,005 | 935.7 | 1,164 | 1,333 | 1,521 | 1,714 | 1,862 |
| Net margin | 11.25% | 11.82% | 10.27% | 12.32% | 13.04% | 13.39% | 13.55% | 14.45% |
| EPS 2 | 1.011 | 0.9635 | 0.8969 | 1.124 | 1.300 | 1.463 | 1.647 | 1.790 |
| Free Cash Flow | 1,201 | 1,055 | - | - | 1,029 | - | - | - |
| FCF margin | 12.8% | 12.4% | - | - | 10.07% | - | - | - |
| FCF Conversion (EBITDA) | 73.96% | 65.73% | - | - | 48.04% | - | - | - |
| FCF Conversion (Net income) | 113.79% | 104.93% | - | - | 77.21% | - | - | - |
| Dividend per Share 2 | 0.3040 | 0.2900 | - | - | 0.2570 | 0.3000 | 0.3400 | - |
| Announcement Date | 3/20/20 | 3/18/21 | 3/24/22 | 3/27/23 | 3/21/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 |
|---|---|
| Net sales 1 | 2,835 |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) | - |
| Net income 1 | 416.1 |
| Net margin | 14.68% |
| EPS | - |
| Dividend per Share | - |
| Announcement Date | 4/25/24 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 1,779 | 2,404 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | 1,201 | 1,055 | - | - | 1,029 | - | - | - |
| ROE (net income / shareholders' equity) | 12.9% | 11.3% | 9.78% | 11.7% | 12.4% | 12.3% | 12.5% | 11.9% |
| ROA (Net income/ Total Assets) | 9.78% | 8.49% | - | - | 8.71% | 9.3% | 9.55% | 9.5% |
| Assets 1 | 10,792 | 11,846 | - | - | 15,298 | 16,351 | 17,944 | 19,595 |
| Book Value Per Share 2 | 8.250 | 8.910 | 9.490 | 9.610 | 10.70 | 11.90 | 13.30 | 14.70 |
| Cash Flow per Share 2 | 1.380 | 1.300 | 1.290 | 1.290 | 1.570 | 1.870 | 2.140 | 2.340 |
| Capex 1 | 239 | 305 | 480 | 522 | 602 | 705 | 797 | 643 |
| Capex / Sales | 2.55% | 3.59% | 5.27% | 5.52% | 5.88% | 6.21% | 6.3% | 5% |
| Announcement Date | 3/20/20 | 3/18/21 | 3/24/22 | 3/27/23 | 3/21/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
21.77
CNY
Average target price
25.58
CNY
Spread / Average Target
+17.50%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +17.04% | 3.07B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B | |
| -3.40% | 157B |
- Stock Market
- Equities
- 600062 Stock
- Financials China Resources Double-Crane Pharmaceutical Co.,Ltd.
